Back to companies

Samsung Biologics Co Ltd: Premium Databases

Samsung Biologics Co Ltd Insights

Remove risk and uncertainty, gain a competitive edge and secure actionable leads with access to company-related investigative journalist content.

A sample of Samsung Biologics Co Ltd Insights data

Headline Published Journalists
Showing 3 of 7 results. Subscribe to unlock more.
Deserunt mollit sunt Lorem laborum do id aliqua dolore 29 Oct 2021 Lorem
Biosimilar interchangeability studies to have limited benefit on US uptake without shifts in legal framework and patient, physician and payer education, experts say 30 May 2018 Shuan Sim
Rituximab biosimilars in Europe likely to see widespread RA uptake; originator preferred in some NHL settings – experts 22 Apr 2016 Alaric DeArment, Alissa Fleck
Samsung RA biosimilar EU uptake tied to perceived cost despite physician concerns – experts 11 Dec 2015 Alissa Fleck, Jennifer C. Smith-Parker


Delivers exclusive investigative journalist content including breaking news and analysis ahead of market-moving events.


Drug Insights:

  • Forward-looking, nuanced, qualitative asset analysis on development, approval & market/reimbursement potential
  • Material intelligence on competitors, including breaking news
  • Insight on companies’ business development needs and strategies

Outsourcing Insights:

Insight on companies’ CRO and business development needs, strategies and relationships


Remove risk and uncertainty

Gain a competitive edge

Secure actionable leads

Premium databases is part of our industry range of products

Subscribe to Company Analytics & gain 12-month access to premium industry data & analytics
Still looking?

Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.


Access more premium companies when you subscribe to Explorer